mounjaro zepbound - Search News

News

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

Forbes · 23h

Eli Lilly: 50% Upside For LLY Stock?

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

MarketWatch on MSN · 1d

Eli Lilly’s weight-loss pill didn’t work so well, and the stock is plunging

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook.

The Financial Times · 2d

Eli Lilly obesity pill disappoints and gives boost to arch-rival Novo Nordisk

Shares in US-based Lilly fell 14.2 per cent on the trial results, while stock in Danish arch-rival Novo Nordisk, the maker of the pioneering Ozempic weight-loss drug, rose 6.7 per cent. Novo Nordisk has been losing share to Lilly in the US in injectable weight-loss drugs.

Barron's on MSN · 2d

Eli Lilly Stock Dives After Earnings Beat. Here’s Why.

Eli Lilly stock tumbled after it released the results for an experimental weight-loss pill study and reported a beat-and-raise quarter early Thursday. The medicine, Orforglipron, resulted in a weight reduction of on average 12.

Pharmaceutical Technology on MSN1d

Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

2don MSN

Lilly raises full-year earnings forecasts on surging demand for weight-loss drug

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

2don MSN

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...

1don MSN

An Oral Weight Loss Medication Just Offered Impressive Results In Clinical Trials

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

ABC Columbia11h

Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says

Now, Eli Lilly says its experimental GLP-1 pill is a success after the first phase-three trial. The company said more than 3,000 adults on the experimental oral medication lowered their weight by an ...

11don MSN

Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

15d

Mounjaro boobs? Weight loss drug can shrink breast cancer tumors, says new study

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

BioPharma Dive1d

Lilly shares fall as obesity pill misses expectations in key trial

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

1don MSN

Science Just Got One Step Closer To An Ozempic-Like Weight Loss Medication In Pill Form

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results